Der Urologe

, Volume 52, Issue 11, pp 1529–1533 | Cite as

Metastasiertes Nierenzellkarzinom

Erstlinien- und Sequenztherapie
Leitthema

Zusammenfassung

Die Einführung neuer medikamentöser Strategien hat die Therapie des metastasierten Nierenzellkarzinoms (NZK) in den vergangenen Jahren grundlegend verändert. Die sog. Target-Therapie bietet heute Patienten mit inkurablem NZK die Chance einer Überlebenszeitverlängerung bei akzeptablem Nebenwirkungsprofil. Verschiedene Tyrosinkinase- und mTOR-Inhibitoren wurden in unterschiedlichen Therapielinien prospektiv randomisiert geprüft, sodass in aktuellen Leitlinien einzelne Substanzen in definierten klinischen Szenarien empfohlen werden. Die optimale therapeutische Sequenz ist noch nicht definiert. Aktuelle Daten sprechen jedoch für den Einsatz eines Tyrosinkinaseinhibitors in der Erstlinienbehandlung. Neue therapeutische Ansatzpunkte werden derzeit in Studien evaluiert.

Schlüsselwörter

Metastasiertes Nierenzellkarzinom Target-Therapie Tyrosinkinaseinhibitor Signaltransduktionsweg Therapiesequenz 

Metastatic renal cell carcinoma

Primary and follow-up treatment

Abstract

Systemic treatment of metastatic renal cell carcinoma has changed fundamentally in recent years. So-called targeted therapy gives patients with incurable renal cell cancer the chance of prolonged survival with acceptable quality of life and manageable side effects. Several tyrosine kinase inhibitors and mTOR inhibitors have been evaluated in various clinical settings within prospective trials. Therefore, recent medical guidelines are able to give recommendations for the management of advanced renal cell carcinoma in daily practice. The optimal therapeutic sequence of the available substances has not been defined until now; however recent data recommend the use of a tyrosine kinase inhibitor as the first line treatment. Besides standard treatment, new approaches are currently being evaluated in clinical trials.

Keywords

Renal cell carcinoma Targeted molecular therapy Tyrosine kinase inhibitor Signal transduction Therapeutic sequence 

Literatur

  1. 1.
    Coppin C, Porzsolt F, Autenrieth M et al (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425Google Scholar
  2. 2.
    Escudier B, Gross Goupil M, Massard C, Fizazi K (2009) Sequential therapy in renal cell carcinoma. Cancer 115(Suppl):2321–2326PubMedCrossRefGoogle Scholar
  3. 3.
    Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRefGoogle Scholar
  4. 4.
    Gore ME, Griffin CL, Hancock B et al (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375:641–648PubMedCrossRefGoogle Scholar
  5. 5.
    Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148PubMedCrossRefGoogle Scholar
  6. 6.
    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRefGoogle Scholar
  7. 7.
    Ljungberg B, Bensalah K, Bex A et al (2013) European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2013 update. http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LRV2.pdfGoogle Scholar
  8. 8.
    Motzer RJ, Bukowski RJ (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608PubMedCrossRefGoogle Scholar
  9. 9.
    Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265PubMedCrossRefGoogle Scholar
  10. 10.
    Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRefGoogle Scholar
  11. 11.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRefGoogle Scholar
  12. 12.
    Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRefGoogle Scholar
  13. 13.
    Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl 2):32–44PubMedCrossRefGoogle Scholar
  14. 14.
    Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) (2012) Krebs in Deutschland 2007/2008, 8. Aufl. RKI, BerlinGoogle Scholar
  15. 15.
    Sternberg C, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Klinik für UrologieHelios Klinikum Erfurt GmbHErfurtDeutschland

Personalised recommendations